GlassScriptPhysician profile
Jona Stead
NPI 1891141552
$2,898.18
in general payments reported to CMS, 2019-2025
26 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 91% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $585 · 2024: $997 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $465.88 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $385.40 | 2023-2025 | |
| Astellas Pharma US INC | $382.34 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $369.11 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $206.10 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $179.74 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $129.80 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $113.80 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.75 | 2025 | Jardiance |
| Almatica Pharma LLC | $71.35 | 2025 | Loreev Xr, Teriparatide |
| Abbott Laboratories | $64.22 | 2025 | Freestyle Libre 3 |
| Lundbeck LLC | $57.92 | 2024-2025 | Vyepti, Rexulti |
| Amgen INC. | $49.01 | 2025 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.05 | 2023-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $47.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $35.98 | 2023-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $35.22 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $28.79 | 2023-2025 | |
| Mylan Specialty L.P. | $24.61 | 2024 | Yupelri |
| Esperion Therapeutics, INC. | $22.81 | 2025 | Nexletol |
| Verona Pharma, INC. | $19.82 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $19.67 | 2023 | Dificid |
| Shield Therapeutics INC | $18.71 | 2023 | Accrufer |
| Mannkind Corporation | $16.38 | 2023 | Afrezza |
| Halozyme INC | $15.42 | 2023 | |
| Axsome Therapeutics, INC. | $13.78 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jona Stead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.